SCHEMBL6786986

SCHEMBL6786986

C/C(=C/C(=O)Nc1ccc(NS(=O)(=O)c2ccccc2)cc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.67
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ALDH1A1 P00352 2/20 0.51
GPR27 Q9NS67 1/20 0.51
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
AKR1C3 P42330 1/20 0.50
GAA P10253 1/20 0.48
MCL1 Q07820 3/20 0.46
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
PLA2G7 Q13093 2/20 0.45
METAP2 P50579 1/20 0.45
BCL2A1 Q16548 2/20 0.45
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790238 0.92 TERT (0.67) TERTMEN1KMT2AALDH1A1GPR27
SCHEMBL6785193 0.90 TERT (0.69) TERTMEN1KMT2AALDH1A1GPR27
SCHEMBL6784867 0.89 TERT (0.55) TERTMEN1KMT2AALDH1A1GPR27
SCHEMBL6786322 0.86 TERT (0.56) TERTMEN1KMT2AALDH1A1GPR27
SCHEMBL6785515 0.86 TERT (0.63) TERTMEN1KMT2AALDH1A1MCL1
SCHEMBL6781944 0.86 TERT (0.75) TERTMEN1KMT2AALDH1A1AKR1C3
SCHEMBL6786594 0.84 TERT (0.72) TERTMEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL6786810 0.83 TERT (0.71) TERTKMT2AAKR1C3KDM4E
SCHEMBL4024783 0.82 TERT (0.80) TERTMEN1KMT2AALDH1A1LMNA
SCHEMBL6786381 0.82 TERT (0.69) TERTMEN1KMT2AALDH1A1GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885MEN1 896/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.